Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis

The method of trans-striatal dialysis has been applied here to the study of the release and metabolism of dopamine (DA) in the awake rat. DA and its acidic metabolites, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), present in the dialysates were separated by high performance liquid chromatography on reverse phase columns and estimated by electrochemical detection. In the awake rat, DA, DOPAC, and HVA could be recovered and quantitated in the dialysates for at least 4 days from the time of implantation of the dialysis tube. At a constant 2-microliters/min flow of Ringer in the dialysis tube, the output of the substances recovered in 20-min samples 24 hr after the implantation was as follows: DA, 0.318 +/- 0.035; DOPAC, 41.3 +/- 4.84; HVA, 32.98 +/- 3.79 (mean picomoles +/- SEM of six 40-microliters samples). The output of DA, DOPAC, and HVA decreased slowly so that 4 days after the implantation the output of DA was reduced by about 35% in respect to the 24-hr values. After a 24-hr recovery, drugs were administered and their effect on DA release and metabolism was investigated. Drugs of different chemical structure and spectrum, but having in common the property of blocking DA receptors and being effective neuroleptics such as haloperidol, sulpiride, and flupentixol, stimulated DA release and DOPAC and HVA output. Threshold doses for this effect were very low, being 0.012 mg/k, s.c., for haloperidol, 2.5 mg/kg, s.c., for (-)-sulpiride, and 0.025 mg/kg, s.c., for cis- flupentixol. This effect was stereospecific as the (+) form of sulpiride and the trans- form of flupentixol were at least 10 to 100 times less potent than their enantiomer. The stimulation of DA release was shorter-lasting than the stimulation of DA metabolism and sedation or catalepsy. Moreover, whereas DA release did not increase by more than 100% over basal values, DOPAC and HVA increased by more than 3 times after maximally effective doses of neuroleptics. gamma- Butyrolactone (200 mg/kg, i.p.) reversed haloperidol (0.1 mg/kg, s.c.), and sulpiride (20 mg/kg, s.c.) induced stimulation of DA release while it potentiated the stimulation of DOPAC and HVA output. These data indicate that stimulation of DA release by neuroleptics is strictly dependent upon stimulation of DA firing and that different mechanisms underline their effects on DA release and on DA metabolism.

[1]  G. Di Chiara,et al.  Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[2]  G. Gessa,et al.  (—)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanesthetized rats , 1983, Brain Research.

[3]  S. Z. Langer,et al.  Stereoselectivity of presynaptic autoreceptors modulating dopamine release. , 1981, European journal of pharmacology.

[4]  S. Z. Langer,et al.  Presynaptic modulation of the release of dopamine from the rabbit caudate nucleus: differences between electrical stimulation, amphetamine and tyramine. , 1981, The Journal of pharmacology and experimental therapeutics.

[5]  K. Iwatsubo,et al.  Diminished responses of nigral dopaminergic neurons to haloperidol and morphine following lesions in the striatum , 1980, Brain Research.

[6]  J. Glowinski,et al.  Effects of the unilateral nigral application of dopaminergic drugs on the in vivo release of dopamine in the two caudate nuclei of the cat. , 1979, European journal of pharmacology.

[7]  G. Di Chiara,et al.  Destruction of post-synaptic dopamine receptors prevents neuroleptic-induced activation of striatal tyrosine hydroxylase but not dopamine synthesis stimulation. , 1978, Life sciences.

[8]  Gallant Dm,et al.  Sulpiride: evaluation of antipsychotic activity in schizophrenic patients. , 1977, Diseases of the nervous system.

[9]  G. Di Chiara,et al.  Localization of nigral dopamine-sensitive adenylate cyclase on neurons originating from the corpus striatum. , 1977, Science.

[10]  G. Chiara,et al.  Postsynaptic receptors are not essential for dopaminergic feedback regulation , 1977, Nature.

[11]  J. Glowinski,et al.  Release of dopamine in vivo from cat substantia nigra , 1977, Nature.

[12]  A. Guidotti,et al.  Dopamine-sensitive adenylate cyclase: location in substantia nigra. , 1977, Science.

[13]  G. Chiara,et al.  A dopamine‐stimulated adenylate cyclase in rat substantia nigra , 1976, Journal of neurochemistry.

[14]  G. Chiara,et al.  Evidence for dopamine receptors mediating sedation in the mouse brain , 1976, Nature.

[15]  S. Snyder,et al.  Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency , 1976, Nature.

[16]  O. Phillipson,et al.  Substantia nigra of the rat contains a dopamine sensitive adenylate cyclase , 1976, Nature.

[17]  B. Bunney,et al.  d-Amphetamine-induced inhibition of central dopaminergic neurons: mediation by a striato-nigral feedback pathway. , 1976, Science.

[18]  T. Jessell,et al.  Release of dopamine from dendrites in rat substantia nigra , 1976, Nature.

[19]  J. Korf,et al.  Dopamine release in substantia nigra? , 1976, Nature.

[20]  S J Young,et al.  Self-inhibition by dopaminergic neurons , 1975, Science.

[21]  P. Seeman,et al.  Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.

[22]  G. Gessa,et al.  SELECTIVE INCREASE OF BRAIN DOPAMINE SYNTHESIS BY SULPIRIDE , 1975, Journal of neurochemistry.

[23]  O. Lindvall,et al.  Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals , 1975, Brain Research.

[24]  A. Guidotti,et al.  Changes of kinetic constant of striatal tyrosine hydroxylase elicited by neuroleptics that impair the function of dopamine receptors. , 1974, Brain research.

[25]  L. Iversen,et al.  The Action of Neuroleptic Drugs on Dopamine-Stimulated Adenosine Cyclic 3',5'-Monophosphate Production in Rat Neostriatum and Limbic Forebrain , 1974 .

[26]  R. Roth,et al.  Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. , 1973, The Journal of pharmacology and experimental therapeutics.

[27]  A. Carlsson,et al.  Evidence for a receptor‐mediated feedback control of striatal tyrosine hydroxylase activity , 1972, The Journal of pharmacy and pharmacology.

[28]  U. Ungerstedt,et al.  Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons. , 1971, European journal of pharmacology.

[29]  B. Hamberger,et al.  Drug-Induced Changes in the Release of 3H-Monoamines from Field Stimulated Rat Brain Slices , 1971 .

[30]  M. Besson,et al.  Increased release of dopane from striatal dopaminergic terminals in the rat after treatment with a neuroleptic: thioproperazine. , 1970, European journal of pharmacology.

[31]  J. Glowinski,et al.  Disposition of newly synthesized amines in cell bodies and terminals of central catechol aminergic neurons. I. Effect of amphetamine and thiorproperazine on the metabolism of CA in the caudate nucleus, the substantia nigra and the ventromedial nucleus of the hypothalamus. , 1970, European journal of pharmacology.

[32]  D. Sharma CHANGES IN THE METABOLISM OF 3, 4-DIHYDROXYPHENYLETHYLAMINE (DOPAMINE) IN THE STRIATUM OF THE MOUSE INDUCED BY DRUGS , 1966 .

[33]  B. Roos Effects of certain tranquillisers on the level of homovanillic acid in the corpus striatum , 1965, The Journal of pharmacy and pharmacology.